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Aims. Diabetes mellitus is a growing health problem worldwide. This study aimed to describe dysglycaemia and determine the
impact of body composition and clinical and lifestyle factors on the risk of progression or regression from impaired fasting glucose
(IFG) to diabetes or normoglycaemia in Australian women.Methods. This study included 1167 women, aged 20–94 years, enrolled
in the Geelong Osteoporosis Study. Multivariable logistic regression was used to identify predictors for progression to diabetes or
regression to normoglycaemia (from IFG), over 10 years of follow-up. Results. At baseline the proportion of women with IFG was
33.8% and 6.5% had diabetes. Those with fasting dysglycaemia had higher obesity-related factors, lower serum HDL cholesterol,
and lower physical activity. Over a decade, the incidence of progression from IFG to diabetes was 18.1 per 1,000 person-years
(95% CI, 10.7–28.2). Fasting plasma glucose and serum triglycerides were important factors in both progression to diabetes and
regression to normoglycaemia. Conclusions. Our results show a transitional process; those with IFG had risk factors intermediate
to normoglycaemics and those with diabetes. This investigation may help target interventions to those with IFG at high risk of
progression to diabetes and thereby prevent cases of diabetes.
1. Introduction
Diabetes mellitus is a complex and often silent chronic
disease that can result in serious consequences, potentially
leading to prematuremortality [1].Diabetes is a serious health
problem; it impacts the lives of approximately 347 million
people worldwide [2] and in Australia, at present, over 1.5
million people have diabetes. It is the fastest growing chronic
disease in Australia, with 280 people newly diagnosed every
day [3]. Impaired fasting glucose (IFG) is defined as a
blood glucose level higher than “normal” but lower than the
threshold for diagnosis of diabetes. Since 2003, the American
Diabetes Association (ADA) has classified IFG as fasting
plasma glucose (FPG) level between 5.5 and 6.9mmol/L
(100 to 125mg/dL), without antihyperglycaemic medication
[4]. It is known that IFG is a risk factor for diabetes and
cardiovascular disease [5–10], but few studies have shown
the epidemiology of progression from IFG to diabetes in the
Australian population.
Research shows that a number of anthropometric and
metabolic factors can influence the risk of developing dia-
betes. These include overweight (body mass index; BMI >
25 kg/m2) and obesity (BMI > 30 kg/m2), which are asso-
ciated with higher risk of developing diabetes compared to
normal weight [11, 12]. An increased waist circumference has
also been shown to increase the risk of developing diabetes
[12].The addition of all other related factors, including hyper-
tension, elevated serum triglycerides (≥1.7mmol/L), lowered
HDL cholesterol (<1.29mmol/L), and IFG (≥5.6mmol/L),
independently increases the risk of developing diabetes in
an additive way [12]. In Australia, the prevalence of these
factors is high; 39.1% of adults are overweight and 20.5% are
obese [13]. A further 20.5% had elevated triglycerides and
28.8% have hypertension. Lifestyle related factors including
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smoking and physical inactivity are also high, 15.6% and
50.2%, respectively. Given these high levels of factors that
have been shown to increase the risk of developing diabetes,
the aim of this study was to describe dysglycaemia, evaluate
the progression of isolated IFG to diabetes or its regression to
normoglycaemia in Australian women, and understand how
body composition and clinical and lifestyle factors affect these
changes.
2. Patients and Methods
2.1. Study Design and Subjects. This study utilises data from
the female arm of the Geelong Osteoporosis Study (GOS), a
population-based study established in the Barwon Statistical
Division (BSD).TheBSD is located in south-easternAustralia
and has a large, stable population of approximately 250,000
with an extended range of cultural and socioeconomic
characteristics. The BSD is representative of the Australian
population, making it ideal for epidemiological studies. A
complete description of the methodology has been published
elsewhere [14]. At baseline, 1993–1997, an age-stratified ran-
dom sample of 1494 women aged 20–94 years was recruited
from Commonwealth electoral rolls with a participation of
77.1%. For this analysis, we excluded 326 women because we
did not have a FPG level or self-report of antihyperglycaemic
medication or diabetes status.Thus, 1167 womenwere eligible
for baseline analysis. In the second phase of this analysis, we
focused on 187 women who had IFG at baseline and whose
diabetes status was reassessed a decade later, 2004–2008.
The study was approved by the Barwon Health Human
Research Ethics Committee, and written, informed consent
was obtained from all subjects.
2.2. Measurements. At baseline, weight and height were
measured to the nearest ±0.1 kg and ±0.1 cm, respectively,
and body mass index (BMI) was calculated as weight/height2
(kg/m2). Subjects were considered obese if BMI ≥ 30.0 kg/m2
[15]. Waist circumference was measured to the nearest
±0.5 cm at the minimum circumference between the lowest
ribs and the iliac crest and was defined as normal if it was
<80.0 cm [16]. Hip circumference (cm) was measured at the
maximal gluteal position; the waist-to-hip ratio (WHR) and
waist-to-height ratio (WHtR) were calculated and defined
as normal if their values were <0.80 [17] and <0.5 [18],
respectively. Whole body scans were performed using a dual-
energy X-ray absorptiometry (DXA; Lunar DPX-L; Lunar,
Madison, WI), which provided estimates of body fat mass
(kg) and “lean” mass (kg), comprising muscle, skin, connec-
tive tissue, and the lean component of adipose tissue—water
and protein [19]. Blood pressure (seated) wasmeasured using
an automated meter (TakedaMedical UA-751). Hypertension
was defined as a systolic pressure ≥140mmHg and/or a
diastolic pressure ≥90mmHg and/or use of antihyperten-
sive medication [16]. Physical activity, alcohol consumption,
current smoking, and medication use were determined by
questionnaire sent out to the participants. Physical activity
was collected from a multiple choice question with the pos-
sible responses being “very active, active, sedentary, limited,
inactive, chair/bedridden, and bedfast.”These responseswere
categorised; “very active” and “active” were pooled as “high”
physical activity and the other categories were collapsed and
defined as “low.”Alcohol consumptionwas collected in a sim-
ilar way, with the responses including “never, less than once
per week, once or twice per week, several times per week,
and every day.” “High” alcohol consumption was defined as
those who consumed alcoholic beverages “several times per
week” or “every day.” All other responses for this question
were classified as “low” alcohol consumption. Women who
reported undertaking regular physical activitywere described
as active; otherwise they were classified as inactive; high alco-
hol consumption was recognised if alcohol was consumed
at least several times a week; antihyperglycaemic medication
use referred to medications taken regularly and currently at
baseline.
Venous blood was collected after an overnight fast at
both baseline and 10-year follow-up; plasma glucose levels
were measured together with serum levels of triglycerides,
high density lipoprotein (HDL) cholesterol, and low den-
sity lipoprotein (LDL) cholesterol using standard laboratory
methods. The method for measuring fasting glucose was an
adaptation of the hexokinase-glucose-6-phosphate dehydro-
genase method [20]. Total cholesterol, high density lipopro-
tein cholesterol (HDL-C), low density lipoprotein choles-
terol (LDL-C), and triglycerides were determined using
commercially available kits (Thermo Fisher Scientific), with
analysis completed on a CDX90 automated clinical chemistry
analyser (Thermo Fisher Scientific), followingmanufacturer’s
instructions.
We also examined the use of lipid lowering medications,
but few women used these agents (𝑛 = 51), and among
those who did, serum lipid results were still outside the
recommended “target range.” Diabetes was by having FPG
≥7.0mmol/L [4] and/or by the self-reported diabetes and/or
by the use of antihyperglycaemic agents [11]. We defined
IFG according to the 2003 ADA diagnostic criteria, 5.5–
6.9mmol/L [4].We also determinedwhether the participants
had metabolic syndrome according to the International
Diabetes Federation (IDF) criteria (2005 revision [21]), which
included measurements of waist circumference, FPG, serum
triglycerides, serum HDL, and hypertension. Briefly, if a
participant had a waist circumference >80 cm and at least
two of the following: (i) raised TG level: ≥1.7mmol/L, or
specific treatment for this lipid abnormality; (ii) reduced
HDL cholesterol: <1.29mmol/L, or specific treatment for this
lipid abnormality; (iii) raised blood pressure: systolic BP ≥
130 or diastolic BP ≥ 85mmHg, or treatment of previously
diagnosed hypertension; (iv) raised FPG ≥ 5.6mmol/L, or
previously diagnosed type 2 diabetes, then the participantwas
considered to havemetabolic syndrome. In addition, sincewe
analysed the data in groups based on normoglycaemia, IFG,
and diabetes, we also examined all of themetabolic syndrome
criteria while excluding FPG.
2.3. Statistical Analysis. Differences in subject characteristics
were identified using Kruskal-Wallis test for continuous
data according to the three glycaemic categories (normal,
IFG, and diabetes) at both baseline and 10-year follow-up.
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Table 1: Subject characteristics according to diabetes status at baseline (normal fasting glucose (NFG), impaired fasting glucose (IFG), and
diabetes). Data are shown as median (interquartile range) or 𝑛 (%).
All (𝑛 = 1167) NFG (𝑛 = 696) IFG (𝑛 = 395) Diabetes (𝑛 = 76) 𝑝
Fasting plasma glucose (mmol/L)∗ 5.3 (5.0–5.7) 5.0 (4.8–5.2) 5.7 (5.6–5.9) 8.1 (6.6–11.1) <0.001
Age (years) 49.3 (35.2–65.0) 42.1 (31.1–42.1) 56.8 (44.0–64.4) 65.2 (59.8–75.3) <0.001
Weight (kg) 66.3 (59.1–76.9) 63.8 (57.3–72.8) 69.5 (61.1–80.8) 71.5 (60.8–83.2) <0.001
BMI (kg/m2) 25.4 (22.6–29.5) 24.5 (22.0–27.7) 26.9 (23.9–31.4) 30.0 (25.6–33.3) <0.001
Body fat mass (kg)∗ 25.3 (19.3–32.8) 23.0 (17.5–30.3) 28.0 (22.1–36.2) 29.5 (21.0–37.1) <0.001
Lean mass (kg)∗ 38.5 (35.7–41.6) 38.4 (35.9–41.3) 38.6 (35.4–42.2) 38.7 (36.1–41.9) 0.69
Waist circumference (cm)∗ 82.6 (74.6–92.7) 79.0 (72.5–87.4) 87.0 (78.6–96.5) 96.4 (87.1–104.6) <0.001
Hip circumference (cm)∗ 103.3 (97.1–111.4) 101.2 (96.2–108.3) 106.3 (99.3–106.3) 108.7 (98.9–119.8) <0.001
WHR (waist-to-hip ratio)∗ 0.80 (0.75–0.84) 0.78 (0.74–0.83) 0.82 (0.77–0.86) 0.88 (0.84–0.91) <0.001
WHtR (waist-to-height ratio)∗ 0.51 (0.46–0.58) 0.49 (0.44–0.55) 0.54 (0.49–0.60) 0.62 (0.56–0.67) <0.001
Systolic blood pressure (mmHg)∗ 121.0 (108.0–136.0) 114.0 (104.0–128.0) 128.0 (115.0–140.0) 141.0 (126.3–163.5) <0.001
Diastolic blood pressure (mmHg)∗ 76.0 (68.0–84.0) 74.0 (66.0–82.0) 79.0 (71.0–86.0) 78.5 (73.0–92.8) <0.001
Serum triglycerides (mmol/L)∗ 1.08 (0.75–1.58) 0.94 (0.69–1.36) 1.26 (0.89–1.71) 2.01 (1.38–2.42) <0.001
Serum HDL cholesterol (mmol/L)∗ 1.21 (0.98–1.47) 1.23 (1.02–1.49) 1.20 (0.95–1.45) 0.98 (0.84–1.26) <0.001
Serum LDL cholesterol (mmol/L)∗ 2.88 (2.30–3.53) 2.71 (2.20–3.36) 3.13 (2.55–3.92) 2.96 (2.23–3.44) <0.001
Obesity (%) 266.0 (22.8) 104.0 (14.9) 124.0 (31.4) 38.0 (49.4) <0.001
Hypertension (mmHg) (%)∗ 427 (36.6) 184 (26.4) 181 (45.8) 62 (81.6) <0.001
Current smoker (%) 189 (16.2) 120 (17.1) 56 (14.2) 13 (17.1) 0.40
High alcohol consumption (%) 210 (18.0) 115 (16.5) 89 (22.5) 6 (7.9) 0.003
Low physical activity (%) 320 (27.4) 146 (21.0) 127 (32.2) 47 (61.8) <0.001
Metabolic syndrome (%) 459 (39.3) 150 (21.6) 252 (63.8) 57 (75.0) <0.001
“Other” metabolic syndromes† 356 (30.5) 150 (21.6) 154 (39.0) 2 (68.4) <0.001
∗Missing data: fasting plasma glucose and blood pressure 𝑛 = 22; body fat and lean mass 𝑛 = 8; waist, hip circumference, waist-to-hip ratio, and waist-to-
height ratio 𝑛 = 13; serum triglycerides 𝑛 = 63; serum HDL cholesterol 𝑛 = 61; serum LDL cholesterol 𝑛 = 59.
†Metabolic syndrome excluding FPG.
The Chi-square test (or Fisher’s exact test) was used to deter-
mine differences between data when expressed in discrete
categories.Multivariable logistic regressionmodels were used
to identify risk factors for progressing from IFG at baseline
to diabetes over the 10 years of follow-up as well as predictors
for regression to normoglycaemia over the same time period.
Odds ratios for potential risk factors were calculated. Lipid
profiles were missing for six participants, so statistical mod-
elling was performed using 𝑛 = 181. The following factors
were included in the logistic model as continuous variables
measured at baseline: age (years), BMI (kg/m2), waist circum-
ference (cm), hip circumference (cm), body fat mass (kg),
leanmass (kg), serumHDL cholesterol (mmol/L), and serum
LDL cholesterol (mmol/L). Additional factors were included
into the same model as categorical variables: fasting glucose
at baseline (above or below 6.1mmol/L), serum triglycerides
(above or below 1.7mmol/L), hypertension (yes/no), current
smoking (yes/no), high alcohol consumption (yes/no), phys-
ical activity (high/low), and metabolic syndrome (yes/no).
Variables to be tested in the final model were identified using
univariate analysis and those with 𝑝 < 0.05 were selected for
inclusion. Variables that contributed to the model by altering
the point estimate for the odds ratio and retained 𝑝 < 0.05
were included in the final model. All logistic models were
adjusted for age. Variables in the final model were tested
for interaction. Statistical analyses were conducted using
the MINITAB software package (Version 16; Minitab, State
College, PA, USA).
2.4. Prevalence and Incidence Rate Calculations. Data from
the Australian Bureau of Statistics 1996 Census Community
Profile Series for the Australian Population (catalogue num-
ber: 2020.0) were used to calculate age-standardised preva-
lence of IFG and diabetes at baseline. The age-standardised
incidence of new diabetes cases from those who had pro-
gressed from IFG was calculated over a 10-year period, using
data from the Australian Bureau of Statistics 2006 Census
Community Profile Series for the Australian Population
(catalogue number 2001.0).
3. Results
3.1. Cross-Sectional Baseline Data . Subject characteristics
at baseline are shown in Table 1. Among 1167 women, 696
(59.6%) had normoglycaemia, 395 (33.8%) had IFG, and
76 (6.5%) met criteria for diabetes. There was a pattern of
increasing median age across the normoglycaemic, IFG, and
diabetes groups. There was an age-related increase in the
prevalence of IFG, ranging from approximately 13% for the
age of 20–29 years and peaking at approximately 50% for the
age of 70–79 years (Figure 1). A similar age-related increase
was observed for diabetes, however, at lower prevalence,
4 Journal of Diabetes Research
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Figure 1: Mean age-specific prevalence of diabetes mellitus and
impaired fasting glucose (IFG) for women at baseline. Error bars
represent 95% CIs.
rising from0.5% for the age of 20–29 and peaking at 22.4% for
those aged 80 years and older. Age-standardised prevalence
of IFG and diabetes was 31.5% (95% CI, 28.4–34.5) and 5.6%
(95% CI, 4.5–6.7), respectively, for the ages of 20 years and
older.
There was a consistent pattern of increasing weight,
BMI, waist circumference, hip circumference, body fat mass,
WHR, WHtR, serum triglycerides, and systolic and diastolic
blood pressure in the groups with dysglycaemia (IFG and
diabetes). Similarly, there was a pattern of increasing obesity
and low physical activity in those with IFG and diabetes.
There was an inverse pattern observed with serum HDL
cholesterol levels; lower levels were observed with increasing
severity of dysglycaemia. More than 60% of women at base-
line with IFG or diabetes had metabolic syndrome, whereas
only approximately 20% of those with normoglycaemia were
affected. When considering metabolic syndrome without
FPG, the results were different. There was a gradual increase
across the groups, with approximately 20% in the normal
plasma glucose group, 39% in the IFG group, and 68% of
those with diabetes.
The women who were excluded from the study due to
insufficient information to classify diabetes status differed
from those who were included in the study. Those who were
excluded were older and had lower weight, shorter height,
lower lean mass, greater waist circumference, higher systolic
and diastolic blood pressure, higher serum triglycerides, and
lower serum HDL cholesterol, with a lower proportion of
smokers and lower mobility.
3.2. Progression from IFG to Diabetes over Follow-Up. All
women with diabetes at baseline were again classified as dia-
betics at the 10-year follow-up (Figure 2). Among 335 women
with normoglycaemia at baseline, 280 (83.6%) remained in
this category at 10-year follow-up, 44 (13.1%) changed to IFG,
and 11 (3.3%) progressed to diabetes. Among 187 women
with IFG at baseline, 62 (33.2%) remained IFG, 104 (55.6%)
reverted to normoglycaemia, and 21 (11.2%) developed dia-
betes. Characteristics of those with IFG at baseline are shown
in Table 2, together with a comparison of characteristics for
those who remained in the IFG group, those who progressed
Normoglycaemia
Impaired fasting 
glucose
Diabetes mellitus
Normoglycaemia
Impaired fasting 
glucose
Diabetes mellitus
Normoglycaemia
Impaired fasting 
glucose
Diabetes mellitus
Normoglycaemia
Impaired fasting 
glucose
Baseline 10-year follow-up
Diabetes mellitus
N= 696
N = 398
N = 76
N = 11
N = 44
N = 287
N = 21
N = 62
N = 107
N = 0
N = 0
N = 29
Figure 2: Numbers of women in each of the three glycaemia groups
who became normoglycaemic and developed impaired fasting
glucose or diabetes over the 10-year follow-up. Note: missing data
for 354 women with normoglycaemia at baseline, 208 women with
impaired fasting glucose at baseline, and 47 women with diabetes at
baseline.
to diabetes, and those who regressed to normoglycaemia.
A comparison between the three groups showed that those
who progressed to diabetes had higher FPG and greater
indices of adiposity including weight, BMI, body fat mass,
waist and hip circumference, WHR, WHtR, systolic blood
pressure, hypertension, serum triglycerides, and obesity; they
also had greater lean bodymass and lower serumHDL.When
analysing metabolic syndrome, the results were similar to
Table 1; more than 70% of those who remained in the IFG
group or progressed to diabetes were affected.Only about half
of those who regressed to normoglycaemia had metabolic
syndrome. The results for metabolic syndrome when FPG
was excluded showed a different pattern; in all glycaemia
groups, fewer women were classified as having metabolic
syndrome. There was a gradual increase in proportions of
those with metabolic syndrome across the groups, from
25.0% in the normoglycaemic group to 46.8% in the IFG
group and 61.9% in the diabetic group.
3.3. Incidence of Progression from IFG to Diabetes over a
Decade. During 1768 person-years of follow-up, 21 of 187
women with IFG at baseline progressed to diabetes. This
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Table 2: Characteristics of subjects with impaired fasting glucose (IFG) at baseline showing those who progressed to diabetes mellitus and
those who regressed to normal fasting glucose (NFG) over the decade of follow-up. Data are shown as median (interquartile range) or 𝑛 (%).
All (𝑛 = 187) NFG (𝑛 = 104) IFG (𝑛 = 62) Diabetes (𝑛 = 21) 𝑝
Fasting plasma glucose (mmol/L)∗ 5.3 (5.0–5.8) 5.7 (5.5–5.8) 5.7 (5.6–6.0) 5.9 (5.7–6.4) <0.001
Age (years) 53.8 (44.0–64.4) 52.4 (41.5–65.0) 55.5 (45.8–64.2) 53.4 (43.7–65.9) 0.73
Weight (kg) 71.3 (62.7–81.1) 67.0 (60.5–76.3) 73.8 (67.1–86.1) 79.9 (74.3–96.0) <0.001
BMI (kg/m2) 27.7 (24.3–31.4) 25.9 (23.8–29.3) 28.8 (25.0–32.6) 30.5 (26.7–35.6) <0.001
Body fat mass (kg) 28.5 (22.8–36.4) 26.7 (21.4–32.8) 30.8 (25.5–38.5) 35.2 (27.8–44.8) <0.001
Lean mass (kg) 39.2 (35.9–42.4) 37.6 (35.1–41.1) 40.5 (37.4–43.6) 42.4 (38.6–45.4) <0.001
Waist circumference (cm) 86.3 (78.0–94.2) 84.3 (74.5–90.3) 90.6 (82.4–101.2) 97.1 (87.0–104.6) <0.001
Hip circumference (cm) 106.3 (100.0–114.6) 103.9 (99.1–109.8) 111.1 (102.7–118.7) 111.9 (104.9–125.6) <0.001
WHR (waist-to-hip ratio) 0.81 (0.77–0.86) 0.79 (0.75–0.85) 0.83 (0.77–0.88) 0.84 (0.81–0.88) 0.004
WHtR (waist-to-height ratio) 0.54 (0.48–0.59) 0.52 (0.47–0.57) 0.56 (0.51–0.62) 0.58 (0.53–0.64) <0.001
Systolic blood pressure (mmHg)∗ 127.5 (114.3–139.8) 121.0 (111.0–135.0) 133.0 (123.0–141.5) 132.0 (120.5–141.0) 0.004
Diastolic blood pressure (mmHg)∗ 79.0 (72.0–86.0) 77.0 (71.0–84.0) 81.0 (73.0–89.8) 80.0 (73.5–88.0) 0.18
Serum triglycerides (mmol/L)∗ 1.13 (0.80–1.61) 1.02 (0.76–1.37) 1.25 (0.88–1.63) 1.84 (1.02–2.88) <0.001
Serum HDL cholesterol (mmol/L)∗ 1.21 (0.95–1.45) 1.26 (1.04–1.57) 1.15 (0.89–1.41) 0.93 (0.83–1.21) 0.002
Serum LDL cholesterol (mmol/L)∗ 3.06 (2.41–3.71) 3.02 (2.35–3.53) 3.00 (2.55–4.03) 3.33 (2.63–3.90) 0.24
Obesity (%) 62 (33.2) 24 (23.1) 27 (43.6) 11 (52.4) 0.004
Hypertension∗ 80 (42.8) 34 (32.7) 34 (54.8) 12 (57.1) 0.008
Current smoker 25 (13.4) 12 (11.5) 10 (16.1) 3 (14.3) 0.7
High alcohol consumption 44 (23.5) 26 (25.0) 15 (24.2) 3 (14.3) 0.57
Low physical activity 44 (23.5) 21 (20.2) 19 (30.7) 4 (19.1) 0.27
Metabolic syndrome (%) 112 (59.9) 51 (49.0) 46 (74.2) 15 (71.4) 0.003
“Other” metabolic syndromes† 68 (36.4) 26 (25.0) 29 (46.8) 13 (61.9) <0.001
∗Missing data: serum fasting plasma glucose 𝑛 = 4; blood pressure 𝑛 = 3; serum triglycerides and serumHDL cholesterol 𝑛 = 6; serum LDL cholesterol 𝑛 = 5.
†Metabolic syndrome excluding FPG.
Table 3: Odds ratios for independent predictors from the logistic regression for progression from impaired fasting glucose (IFG) at baseline to
diabetes or regression to normoglycaemia over a 10-year follow-up period in women. Of 181 women, 21 developed diabetes over the follow-up
period and 104 reverted to normoglycaemia. Data are presented as OR (95% CI).
Progression to diabetes 𝑝 value Regression to normoglycaemia 𝑝 value
Fasting plasma glucose ≥6.1mmol/L 5.75 (1.86, 17.78) 0.002 0.19 (0.05, 0.70) 0.012
Serum triglycerides ≥1.7mmol/L 7.86 (2.76, 22.38) <0.001 0.46 (0.26, 0.81) 0.008
Lean mass (kg) NS NS 0.87 (0.80, 0.94) 0.001
NS = not significant.
corresponded to an age-standardised incidence rate of 18.1
per 1,000 person-years (95% CI, 10.7–28.2).
3.4. Risk Factors for IFG to Diabetes. In amultivariablemodel
including 181 participants, FPG and serum triglycerides were
identified as independent risk factors for progressing from
IFG to diabetes over the ensuing decade (Table 3). The odds
ratio for progressing to diabetes was nearly sixfold greater
if FPG ≥6.1mmol/L (OR 5.75 (95% CI, 1.86–17.78), 𝑝 =
0.002) and nearly eightfold greater if serum triglycerides
≥1.7mmol/L (OR 7.86 (95% CI, 2.76–22.38), 𝑝 < 0.001).
These relationships were not explained by differences in age,
body fatness, blood pressure, health behaviours, serum HDL
cholesterol levels, or serum LDL cholesterol levels. We also
examined metabolic syndrome as a predictor for progression
from IFG to diabetes, but it was not significant (OR 1.85, 95%
CI, 0.59–5.84).
3.5. Predictors for Regression from IFG to Normoglycaemia.
A multivariable model also showed that FPG, lean mass,
and serum triglycerides were independent predictors of
regression from IFG to normoglycaemia (Table 3). The odds
ratio for FPG was 0.19 (95% CI, 0.05–0.70, 𝑝 = 0.012),
meaning that thosewith higher FPGhad a reduced likelihood
of regressing to normoglycaemia over the 10 years of follow-
up. Serum triglycerides and lean mass followed similar
patterns, with odds ratios of 0.46 (0.26–0.81, 𝑝 = 0.008)
and 0.87 (95% CI, 0.80–0.94, 𝑝 = 0.001), respectively.
No interaction terms were identified. In addition, we also
analysed absence of metabolic syndrome as a predictor of
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regression to normoglycaemia; however, the results were not
significant (OR 0.61, 95% CI, 0.28–1.34).
4. Discussion
This longitudinal and cross-sectional population-based study
reports on progression to diabetes and regression to normo-
glycaemia from IFG in a female Australian cohort over a
10-year period. Individuals with IFG or diabetes at baseline
had older age, greater indices of adiposity, higher blood
pressure, serum triglycerides, serumLDL cholesterol, alcohol
consumption, and more physical inactivity. High FPG and
high serum triglycerides were identified as independent pre-
dictors for the progression from IFG to diabetes, while lower
levels of FPG and serum triglycerides were independent
predictors of regression to normoglycaemia. Lean mass was
also an independent predictor for the regression from IFG to
normoglycaemia. We also analysed metabolic syndrome as a
risk factor, but it was not significant in statistical analyses.
Indeed, it has been shown that metabolic syndrome may
not be more effective than the individual components that
are included in its calculation [22], which may explain why
we did not observe it as a predictive factor for diabetes
classifications.
There have been many studies that report on the inci-
dence of IFG and risk factors for progression to diabetes,
which are collated in a meta-analysis by Morris et al. [23].
However, many of them did not use the ADA criteria and
consequently are not directly comparable to our study. One
study, which did use the ADA criteria [8], investigated a
cohort of European men and women and reported similar
results to our study for IFG (compared to normoglycaemia)
including increased age, BMI, waist circumference, serum
HDL cholesterol, serum triglycerides, and blood pressure.
They also reported an incidence for progression from IFG
to diabetes of 10.6 per 1,000 person-years (95% CI: 8.1–13.9),
similar in magnitude to our value. Differences between our
study and the Forouhi study include that the latter considered
adults aged between 40 and 69 years, whereas we investigated
the entire adult age range (20–94 years). Additionally, their
study included a higher proportion of adults living in more
affluent areas whereas our study included adults from range
of socioeconomic levels [19].
There is also a prospective study from the USA which
reported diabetes incidence using data frommen andwomen
aged 30 years or older [24]. In this study 17.1% of those
with IFG developed diabetes within five years, corresponding
to an incidence rate of 37.4 per 1,000 person-years (95%
CI, 36.0–38.9). Differences between study subjects, such as
the inclusion of men and women, sample size, levels of
adiposity, life style/environment, and ethnicity, may account
for differences between our results and the results of this
study.
Other studies have examined risk factors for the pro-
gression of IFG to diabetes. One such study by Bonora
et al. [11] reported that age, BMI, IFG, and impaired glucose
tolerance (IGT) were all predictors of diabetes. Aekplakorn
et al. [25] developed a model of risk factors including age,
BMI, waist circumference, hypertension, and history of
diabetes (parents/siblings), with only a small increase in qual-
ity of their model when IFG, IGT, serum HDL cholesterol,
and/or triglycerides were included. Another investigation in
Chinese participants showed that, after adjustment for age,
sex, smoking, alcohol consumption, and a family history of
hypertension, obesity, diabetes, and hyperlipidaemia, only
IFG was an independent risk factor for diabetes [26]. The
results from our analysis are similar, showing that IFG (FPG
levels) and serum triglycerides were independent predictors
of progression from IFG to diabetes. We did not observe
an independent association between diabetes and age, BMI,
WC, WHR, or hypertension; however, individuals with IFG
were more likely to be overweight and consequently have
higher BMI, waist circumference, and so forth (see Table 2).
Therefore, IFG alone may act as a surrogate for fat mass and
obesity in this cohort.
There have been studies investigating the regression from
IFG to normoglycaemia, almost always using medication
rather thanmodifiable lifestyle factors [27]. In our study, none
of the participants classified with IFG (by definition) were
taking any antihyperglycaemic agents that would influence
their regression to normoglycaemia. Our data showed that
relatively low FPG, serum triglycerides, and lean mass were
predictors for regression to normoglycaemia and in addition,
measures of adiposity were lower in those who regressed
to normoglycaemia. These predictors are associated with
improved health, except for higher lean mass, which was
associated with nonregression. In order to investigate this,
we calculated a ratio of lean/total weight for IFG subjects
who either regressed to normoglycaemia or remained in
the IFG group at the 10-year follow-up of the study (data
not shown). Those who regressed to normoglycaemia had a
higher lean/total weight ratio (0.56) than thosewho remained
in the IFG group (0.53) (𝑝 = 0.006) (data not shown). This
indicates that those who remained in the IFG group had
higher lean mass, but it contributed a lower proportion of
total body weight than those who regressed to normogly-
caemia.
Our study has some strengths and limitations. The major
strengths are that the participants were randomly selected,
which is important when estimating the age-standardised
prevalence of diabetes in the region. Our study also included
a wide age range with considerable follow-up time. We also
used a robust method for the diagnosis of diabetes, which
included a FPG measurement, self-report, and medication
use. The study also utilised whole body densitometry for
the assessment of body fat mass, lean mass, and BMI
more accurately than typical anthropometric measurements.
However, we acknowledge that there are some limitations to
the present study.Most of the participants were white females
and our resultsmay not be generalisable to other populations.
The women who were excluded from the study due to
insufficient information to classify diabetes status differed
from those who were included in the study. Those who were
excluded were older and had lower weight, shorter height,
lower lean mass, greater waist circumference, higher systolic
and diastolic blood pressure, higher serum triglycerides,
lower serum HDL cholesterol, with a lower proportion of
smokers and lower mobility. We acknowledge that this is
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a limitation in determining the incidence of progression
to diabetes in this study and our results are possibly a
conservative estimate. However, our estimate is comparable
to others reported in the literature. Additionally, there was
some attrition during the course of the study and there may
have been differential loss to follow-up; it was not possible to
determine if those lost to follow-up were more or less likely
to have developed diabetes than those who were retained in
the study. Harmonization of the IDF and ADA criteria has
resulted in a small increase in the prevalence of the metabolic
syndrome in some populations. Given that the impact of
the metabolic syndrome on the likelihood of progressing to
diabetes was far from significant (Supplementary Table avail-
able online at http://dx.doi.org/10.1155/2015/373762), using
different criteria for defining the metabolic syndrome is
unlikely to impact our reported findings. Finally, we did rely
on some self-reported data such as medication use, smoking,
alcohol consumption, and physical activity, whichmay not be
accurate, but it is important to note that most of our analyses
were based on biochemical and clinical measurements.
5. Conclusions
In conclusion, we achieved the study objective, to describe
the epidemiology of dysglycaemia and the impact of body
composition and clinical and lifestyle factors on the risk of
progression to diabetes and regression to normoglycaemia
in a cohort of Australian women. We report that women
with dysglycaemia had higher obesity-related factors and
lower serum HDL cholesterol. There was an age-related
increase in the prevalence of IFG and diabetes. FPG and
serum triglycerides were revealed as independent predictors
of progression from IFG to diabetes. Independent predictors
for regression from IFG to normoglycaemia included FPG,
serum triglycerides, and lean mass.
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